Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 9, 2008, Pages 924-929

  Cereto, Ferran ^a   Herranz, Xavier ^a   Moreno, Eva ^b   Andreu, Antònia ^b   Vergara, Mertxe ^c   Fontanals, Dionisia ^d,e   Roget, Mercè ^f   Simó, Maria ^f   González, Antonio ^a   Prats, Guillem ^b   Genescà, Joan ^a,g  

^a HUVH   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Hospital Universitari Parc Taulí   (Spain)

^e PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^f Brain   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Escherichia coli; Immunosuppression; Liver cirrhosis; Spontaneous bacterial peritonitis; Virulence factors

Indexed keywords

ALBUMIN; CEFOTAXIME; CEFTRIAXONE; COTRIMOXAZOLE; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VIRULENCE FACTOR; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BACTERIAL VIRULENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HOST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; MALE; MORTALITY; NONHUMAN; PHYLOGENY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PYELONEPHRITIS; TERTIARY HEALTH CARE; AGED; CLINICAL TRIAL; DRUG EFFECT; ESCHERICHIA COLI INFECTION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNE DEFICIENCY; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOGENICITY; PERITONITIS; PROGNOSIS; PROSPECTIVE STUDY; VIRULENCE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PERITONITIS; PHYLOGENY; PROGNOSIS; PROSPECTIVE STUDIES; PYELONEPHRITIS; VIRULENCE;

EID: 58149299944     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282fc7390     Document Type: Article

References (36)

1. Llovet JM, Moitinho E, Sala M, Bataller R, Rodriguez-Iglesias P, Castells A, et al. Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. J Hepatol 2000; 33:423-429.
2. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341:403-409.
3. Cereto F, Molina I, González A, Del Valle O, Esteban R, Guardia J, et al. Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis. Aliment Pharmacol Ther 2003; 17:695-701.
4. Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000; 32:142-153.
5. Aparicio JR, Such J, Pascual S, Arroyo A, Plazas J, Girona E, et al. Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences. J Hepatol 1999; 31:277-283.
6. Dupeyron C, Managaney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Ch 1994; 38:340-344.
7. Carratala J, Fernández-Sevilla A, Tubau F, Domínguez MA, Gudiol F. Emergence of fluoroquinolone-resistent Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Ch 1996; 40:503-505.
8. Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-148.
9. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli pylogenetic group. Appl Environ Microbiol 2000; 66:4555-4558.
10. Johnson JR, Stell AL. Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. J Infect Dis 2000; 181:261-272.
11. Picard B, Sevali J, Gouriou S, Duriez P, Brahimi N, Elion J, et al. The link between phylogeny and virulence in Escherichia coli extraintestinal infection. Infect Immun 1999; 67:546-553.
12. Moreno E, Planells I, Prats G, Planes AM, Moreno G, Andreu A. Comparative study of Escherichia coli virulence determinants in strains causing urinary tract bacteremia versus strains causing pyelonephritis and other sources of bacteremia. Diagn Microbiol Infect Dis 2005; 53:93-99.
13. Moreno-Pujol E, Prats-Pastor G, Planells-Romeo I, Planes-Reig AM, Pérez-Berezo T, Andreu-Domingo A. Caracterization of Escherichia coli isolates derived from phylogenetic groups A and B1 causing extraintestinal infection. Enferm Infecc Microbiol Clin 2006; 24:483-489.
14. National Committee for Clinical Laboratory Standards. Perfomance standard for antimicrobial disk susceptibility test. Approved Standard M2-A4. Villanova, Pennsylvania: National Committee for Clinical Laboratory standards; 1990.
15. Campillo B, Dupeyron C, Richardet JP, Mangeney N, Leluan G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26:1066-1070.
16. Cereto F, Genescà J, Smithson A, Gonzalez A, Moreno G, del Valle Ortiz O, et al. Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role? Eur J Gastroenterol Hepatol 2002; 14:81-83.
17. Llovet JM, Bartolí R, Planas R. Intestinal bacterial translocation. Gastroenterol Hepatol 1996; 19:374-382.
18. Singh N, Gayowsky T, Yu VL, Wagener MM. Trimetroprim-sulfamethoxazol for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trail. Ann Intern Med 1995; 122:595-598.
19. Alvarez RF, Mattos AA, Correa EB, Cotrim HP, Nascimento TV. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis. Arq Gastroenterol 2005; 42:256-262.
20. Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57:780-783.
21. Ena J, Arjona F, Martinez-Peinado C, Lopez-Perezagua Mdel M, Amador C. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Urology 2006; 68: 1169-1174.
22. García O, Rodríguez C, Fernández J, Navasa M, Ginès P, Arroyo V. Infecciones bacterianas por Escherichia coli con betalactamasas de espectro ampliado (BLEA) en pacientes cirróticos. Incidencia y factores pronósticos. Gastroenterol Hepatol 2007; 30 (Suppl 1):162 (abstract).
23. Park YH, Lee HC, Song HG, Jung S, Ryu SH, Shin JW, et al. Recent increase in antibiotic-resistant microorganisms in patients with spontaneous bacterial peritonitis adversely affects the clinical outcome in Korea. J Gastroenterol Hepatol 2003; 18:927-933.
24. Sandhu BS, Gupta R, Sharma J, Singh J, Murthy NS, Sarin SK. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol 2005; 20:599-605.
25. Toledo C, Salmeron JM, Rimola A, Navasa M, Arroyo V, Llach J, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993; 17:251-257.
26. Andreu M, Sola R, Sitges-Serra A, Alia C, Gallen M, Vila MC, et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterology 1993; 104:1133-1138.
27. Guarner C, Sola R, Soriano G, Andreu M, Novella MT, Vila MC, et al. Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels. Gastroenterology 1999; 117:414-419.
28. Shaw E, Castellote J, Santin M, Xiol X, Euba G, Gudiol C, et al. Clinical features and outcome of spontaneous bacterial peritonitis in HIV-infected cirrhotic patients: a case-control study. Eur J Clin Microbiol Infect Dis 2006; 25:291-298.
29. Song JY, Jung SJ, Park CW, Sohn JW, Kim WJ, Kim MJ, et al. Prognostic significance of infection acquisition sites in spontaneous bacterial peritonitis: nosocomial versus community acquired. J Korean Med Sci 2006; 21:666-671.
30. Otto G, Magnusson M, Svensson M, Braconier JH, Svanborg C. Pap genotypes and P fimbrial expression in Escherichia coli causing bacteremic and nonbacteremic febrile urinary tract infection. Clin Infect Dis 2001; 32:1523-1531.
31. Ruiz J, Simon K, Horcajada JP, Velasco M, Barranco M, Roig G, et al. Differences in virulence factors among clinical isolates of Escherichia coli causing cystitis and pyelonephritis in women and prostatitis in men. J Clin Microbiol 2002; 40:4445-4449.
32. Moreno E, Prats G, Sabaté M, Pérez T, Johnson JR, Andreu A. Quinolone, fluoroquinolone and trimethoprim/sulfamethoxazole resistance in relation to virulence determinants and phylogenetic background among uropathogenic Escherichia coli. J Antimicrob Chemother 2006; 57:204-211.
33. Blázquez R, Menasakvas A, Carpena Y, Ramírez C, Guerrero C, Moreno S. Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli. Eur J Clin Microbiol 1999; 18:503-505.
34. Velasco M, Horcajada JP, Mensa J, Moreno Martínez A, Vila J, Martinez JA et al. Decreased invasive capacity of quinolone-resistant Escherichia coli in patients with urinary tract infections. Clin Infect Dis 2001; 33:1682-1686.
35. Johnson JR, Orskov I, Orskov F, Goullet P, Picard B, Moseley SL, et al. O, K and H antigens predict virulence factors, carboxylesterase B pattern, antimicrobial resistance, and host compromise among Escherichia coli strains causing urosepsis. J Infect Dis 1994; 169: 119-126.
36. Maslow JN, Mulligan ME, Adams KS, Justis JC, Arbeit RD. Bacterial adhesins and host factors: role in the development and outcome of Escherichia coli bacteremia. Clin Infect Dis 1993; 17:89-97.